Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: Tuesday, June 17, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Jakubowiak says ideally, researchers aim to create a drug or drug combination that is more active with less toxicity. In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm. There was also a higher rate of thrombocytopenia and other hematological toxicities. However, all of the toxicities were mostly manageable and did not impact the outcome, Jakubowiak says.

More details are needed to get a better understanding of the toxicity profile of this combination in this setting, Jakubowiak says.

Online CME Activities
Free CME from PER
9th Annual Multidisciplinary Symposium on Head and Neck Cancer® Medical Crossfire®
Clinical Challenges in the Management of Melanoma
Advances in ImmunoOncology: Intralesional Oncolytic Immunotherapy in Melanoma
Updates in the Treatment of Lung Cancer
More Reading
$auto_registration$